fibrobiologics.com (FBLG): רווח נקי למניה (EPS TTM)
Is it worth investing in FibroBiologics, Inc. (FBLG), which has developed a unique system for combating multiple sclerosis and disc degeneration? The rolling 12-month net income per share provides the answer, and its current level is -5.59. FibroBiologics, Inc. (FBLG) is patenting tissue regeneration methods, offering affordable stem cell alternatives for cancer therapy. However, financial stability is currently based exclusively on venture capital and equity offerings.
פילוחים אנליטיים של חברת FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG) is developing a unique fibroblast-based tissue regeneration technology protected by an extensive patent portfolio. The monetization of these innovations directly impacts the calculation of net income distributable to all shareholders. This indicator measures the business's actual ability to generate equity income, stripped of one-time factors. Analyzing the trend of the rolling 12-month earnings per share allows for an assessment of the operating model's sustainability. The stability of this line confirms the company's fundamental strength.
